RT Journal Article
SR Electronic
T1 Integrative proteomic analyses across common cardiac diseases yield new mechanistic insights and enhanced prediction
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.19.23300218
DO 10.1101/2023.12.19.23300218
A1 Schuermans, Art
A1 Pournamdari, Ashley B.
A1 Lee, Jiwoo
A1 Bhukar, Rohan
A1 Ganesh, Shriienidhie
A1 Darosa, Nicholas
A1 Small, Aeron M.
A1 Yu, Zhi
A1 Hornsby, Whitney
A1 Koyama, Satoshi
A1 Januzzi, James L.
A1 Honigberg, Michael C.
A1 Natarajan, Pradeep
YR 2023
UL http://medrxiv.org/content/early/2023/12/19/2023.12.19.23300218.abstract
AB Cardiac diseases represent common highly morbid conditions for which underlying molecular mechanisms remain incompletely understood. Here, we leveraged 1,459 protein measurements in 44,313 UK Biobank participants to characterize the circulating proteome associated with incident coronary artery disease, heart failure, atrial fibrillation, and aortic stenosis. Multivariable-adjusted Cox regression identified 820 protein-disease associations—including 441 proteins—at Bonferroni-adjusted P<8.6×10−6. Cis-Mendelian randomization suggested causal roles that aligned with epidemiological findings for 6% of proteins identified in primary analyses, prioritizing novel therapeutic targets for different cardiac diseases (e.g., interleukin-4 receptor for heart failure and spondin-1 for atrial fibrillation). Interaction analyses identified seven protein-disease associations that differed Bonferroni-significantly by sex. Models incorporating proteomic data (vs. clinical risk factors alone) improved prediction for coronary artery disease, heart failure, and atrial fibrillation. These results lay a foundation for future investigations to uncover novel disease mechanisms and assess the clinical utility of protein-based prevention strategies for cardiac diseases.Competing Interest StatementJ.L.J. is a Trustee of the American College of Cardiology and reports board membership of Imbria Pharmaceuticals; grant support from Abbott Diagnostics, Applied Therapeutics, AstraZeneca, Bayer, HeartFlow, Innolife and Roche; previous consulting income from Abbott Diagnostics, AstraZeneca, Bayer, Beckman-Coulter, Jana Care, Janssen, Novartis, Quidel, Roche Diagnostics and Siemens; clinical endpoint committee/data safety monitoring board membership for Abbott, AbbVie, CVRx, Pfizer and Takeda. M.C.H. reports consulting fees from CRISPR Therapeutics and Comanche Biopharma; advisory board service for Miga Health; and grant support from Genentech. P.N. reports research grants from Allelica, Amgen, Apple, Boston Scientific, Genentech / Roche, and Novartis; personal fees from Allelica, Apple, AstraZeneca, Blackstone Life Sciences, Creative Education Concepts, CRISPR Therapeutics, Eli Lilly & Co, Foresite Labs, Genentech / Roche, GV, HeartFlow, Magnet Biomedicine, Merck, and Novartis; scientific advisory board membership of Esperion Therapeutics, Preciseli, and TenSixteen Bio; scientific co-foundership of TenSixteen Bio, equity in MyOme, Preciseli, and TenSixteen Bio; and spousal employment at Vertex Pharmaceuticals (all unrelated to the present work).Funding StatementA.S. is supported by the Belgian American Educational Foundation. J.L.J. is supported in part by the Adolph M. Hutter MD Professorship. M.C.H. is supported by the U.S. NHLBI (K08HL166687) and AHA (940166, 979465). P.N. is supported by the Paul & Phyllis Fireman Endowed Chair in Vascular Medicine from the Massachusetts General Hospital and the U.S. NHLBI (R01HL127564).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Mass General Brigham Institutional Review Board gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes